

Effects of Postbiotic from Bacteriocin–Like Inhibitory Substance Producing *Enterococcus faecalis* on Toxigenic *Clostridioides difficile*

Pawarisa Luenglusontigit, M.Sc.¹, Ponsit Sathapondecha, Ph.D.², Phanvasri Saengsuwan, M.Sc.¹, Komwit Surachat, Ph.D.¹, Panadda Boonserm, Ph.D.³, Kamonnut Singkhamanan, Ph.D.¹

¹Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.

²Division of Biological Science, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.

³Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand.

Received 11 August 2022 • Revised 23 October 2022 • Accepted 2 November 2022 • Published online 6 January 2023

Abstract:

Objective: To determine the activities of postbiotics, prepared from bacteriocin–like producing *Enterococcus faecalis* (*E. faecalis*) against *Clostridioides difficile* (*C. difficile*) and its spores, and to assess the safety of postbiotics in vivo.

Material and Methods: Bacteriocin production of *E. faecalis* PK1201 was screened by proteolytic enzyme treatment, and bacteriocin–encoding genes were characterized by whole genome sequencing. A postbiotic of *E. faecalis* PK1201 was prepared using neutralized cell–free supernatant or bacterial cell lysate, which was then used to screen for antimicrobial activity via agar well diffusion. The lyophilized cell–free supernatant (LCFS) was further determined for its minimum inhibitory concentration (MIC) against *C. difficile* 630. The morphological changes of *C. difficile* were observed under scanning electron microscopes (SEM). Subsequently, the LCFS at sub–MIC and MIC were used to evaluate anti–spore germination activity. Finally, the safety of postbiotics was accessed using the *Galleria mellonella* model.

Results: *E. faecalis* PK1201 carried enterolysin A encoding gene. For postbiotic preparation, only LCFS exhibited antimicrobial activity, and the activity was completely lost after proteinase K treatment; indicating the existence of bacteriocin. LCFS showed anti–*C. difficile* with MIC of 18.2±6.9 mg/mL. The SEM images demonstrated shorter destruction of *C. difficile* cells after being treated with LCFS. Interestingly, LCFS at the MIC and sub–MIC revealed anti–spore germination

This paper was from the 1st Annual Health Research International Conference (AHR–ICON, August 1–2, 2022).

Contact: Kamonnut Singkhamanan, Ph.D.

Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.

E–mail: skamonnun@medicine.psu.ac.th

© 2023 JHSMR. Hosted by Prince of Songkla University. All rights reserved.

This is an open access article under the CC BY–NC–ND license

(<http://www.jhsmr.org/index.php/jhsmr/about/editorialPolicies#openAccessPolicy>).

J Health Sci Med Res

doi: 10.31584/jhsmr.2023918

www.jhsmr.org

activity against toxigenic *C. difficile* compared to the control. LCFS showed no acute toxicity in *G. mellonella* at the tested concentration.

Conclusion: The powerful activity and safety of LCFS shed light on the role of postbiotics in pharmaceutical products to control CDI.

Keywords: bacteriocin, *Clostridioides difficile*, *Enterococcus faecalis*, postbiotics, spore

Introduction

Clostridioides difficile infection (CDI) is considered the main cause of nosocomial diarrhea. CDI affects almost half a million illnesses in the United States every year¹. *C. difficile* is a Gram-positive, spore-forming, toxin-producing anaerobic bacteria, which can produce toxin A and/or toxin B that initiates diarrhea and colitis². The current standard of care for CDI involves antibiotic treatments with vancomycin or fidaxomicin, which not only kills *C. difficile*, but also affects other gut benefit bacteria; causing up to 12–64% recurrence risk³. Thus, novel adjunctive therapies that can improve outcomes are required.

Probiotics are defined as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host”, which can defeat diseases and combat gut pathogens⁴. They are considered to defend gut health against infections through various mechanisms; including the generation of antimicrobial compounds; such as hydrogen peroxide, organic acids, and bacteriocins or bacteriocin-like substances⁵. Among them bacteriocins, proteinaceous or peptidic toxins produced by bacteria have great attractiveness as they are safe, effective and natural inhibitors against various pathogens⁶. Moreover, systematic reviews have elucidated that some probiotic bacteria; especially lactic acid bacteria (LAB) and *Bifidobacterium* spp., are able to prevent 17% of antibiotic-associated diarrhea as well as treat 3% of CDI in a clinical trial^{7,8}. Some *Enterococcus* strains, which are LAB, have been proven to inhibit *C. difficile*. *E. faecium* NM1015, *E. faecalis*

NM815, and *E. faecalis* NM915 have been shown to inhibit *C. difficile* in vivo⁹. Additionally, the study of Romyasamit et al., 2020 has found anti-*C. difficile* activity in *E. faecalis* isolates. These could be promising probiotics with potential applications in preventing CDI¹⁰. Although, probiotics might be effectively used to treat CDI, their clinical application in immunocompromised patients is limited due to the possibility of bacteremia and sepsis¹¹.

Hence, postbiotics were invented to reduce the risk of using probiotics. They refer to inanimate microorganisms and/or their components that confer a physiological benefit on the host¹². Otherwise, postbiotics are products or metabolic byproducts that are secreted into cell-free supernatant (CFS) of bacterial suspension during the growth of probiotics^{13,14}. Therefore, several postbiotic compounds, such as bacterial cell lysate, enzymes, organic acids and bacteriocins, have demonstrated antimicrobial activity against Gram-positive and Gram-negative microorganisms¹⁵. For instance, *Enterococcus avium*'s cells lysate retained antibacterial effects against *Pseudomonas aeruginosa*¹⁶. In addition, LAB strains commonly produce bacteriocins; including, nisin A, secreted from *Lactococcus* and *Streptococcus* species have a broad spectrum of activity against other LAB and other Gram-positive organisms, including *C. difficile*, by causing changes in the bacterial membrane¹⁷.

The studies regarding postbiotics are now of interest; however, few reports concerning postbiotics being used in treating or preventing CDI, and the activity of postbiotics

from *E. faecalis* against *C. difficile* have not been elucidated. Thus, this study aimed to characterize and verify the activity of bacteriocin-like inhibitory substances producing *E. faecalis*'s postbiotic against toxigenic *C. difficile*, and assess the safety of postbiotic to provide a novel, alternative therapeutic option for CDI patients.

Material and Methods

Materials

Brain heart infusion agar (HiMedia, India), Brain heart infusion broth (HiMedia, India), deoxyribonucleic acid (DNA) extraction kits (Tiangen Biotech, China), EDTA (Amresco, USA), Ethanol (JT Baker, USA), HEPES buffer (Sigma-Aldrich, USA), L-cysteine (Merck Millipore, Germany), Tris (Thermo Fisher Scientific, UK), Phosphate Buffered Saline (PBS), pH 7.4 (HiMedia, India), Proteinase K (Amresco, USA), Taurocholic acid sodium salt (Sigma-Aldrich, USA), Tryptose Broth, (HiMedia, India), Sarcosyl (Amresco, USA), Yeast extract (Sigma-Aldrich, USA)

Methods

1. Characterization of bacteriocin-producing *E. faecalis* by proteolytic treatment

1.1 Proteinase K treatment

A culture medium or 500 mg/mL of postbiotic containing protein, having respective anti-*C. difficile* activity was tested by treating with proteinase K at a final concentration of 10 mg/mL and compared with those untreated. The mixture was then incubated at 30 °C for 2 hours. The reaction was stopped by heating the culture at 80 °C for 10 minutes: the antimicrobial activity was evaluated by agar spot on lawn assay.

1.2 Agar spot on lawn assay

The agar spot-on lawn assay was performed to screen for anti-*C. difficile* activity. Briefly, 10 µL of culture medium, treated with or without proteinase K, was dropped on the agar lawn of *C. difficile* 630, purchased from the

American Type Culture Collection (ATCC). This was followed by incubation at 37 °C for 48 hours in an anaerobic environment. After the incubation time, the inhibitory zone was observed¹⁸. The inhibitory zone disappeared, indicating that the active compound is a protein or the postbiotics might be composed of bacteriocin or bacteriocin-like inhibitory substances¹⁹.

2. Characterization of bacteriocin-producing *E. faecalis* by genome analysis

2.1 DNA extraction and whole genome sequencing

Genomic DNA of *E. faecalis* PK 1201 was extracted with commercial DNA extraction kits: TIANamp Genomic DNA kit (Tiangen Biotech, Beijing, China). Then, the genomic DNA was sequenced using the BGISEQ-500 (BGI, Beijing, China) to generate 150-bp paired-end reads.

2.2 Genome assembly, annotation, and bioinformatics analysis

The raw sequence reads of the sample were first cleaned and trimmed by Trimmomatic v0.40²⁰ using default parameters. The trimmed reads were then assembled using spades v3.13.1²¹ to generate draft assemblies of all three samples. The assembly quality evaluations were performed by Quast v5.0.2²². The genome was then annotated using Prokka v1.12²³ to identify genomic features for use in further downstream analysis. Bacteriocins were predicted using the Bacteriocin Genome mining tool (BAGEL) 4 server²⁴.

3. Postbiotic preparation

Firstly, a postbiotic was prepared using both bacterial cell lysate and CFS from *E. faecalis* PK 1201.

3.1 Bacterial cell lysate preparation

The sonication-kill cell method was used for the preparation of bacterial cell lysate. Briefly, the overnight culture of *E. faecalis* was centrifuged for 10 minutes at 5,714 g at 4 °C to remove the supernatant and resuspend it in HEPES buffer. Then, the cell suspension was killed by sonication (60% amplitude, pulse 45s, pause 1 min)

for 5 min to receive bacterial cell lysate and utilized as a postbiotic²⁵.

3.2 LCFS

The culture supernatant of *E. faecalis* from 3.1 was neutralized to pH 6.5 with 1 N NaOH before it was filtered through a 0.22 µm microfilter to eliminate bacterial cells. The CFS was then lyophilized (Vacuum pressure at 0.128 millibars, 21 °C for 24 hours) to obtain LCFS. This was then diluted in 20 mM HEPES buffer to the starter concentration of 500 mg/mL and utilized as a postbiotic.

3.3 Agar spot on lawn assay

Both postbiotics were screened for their antimicrobial activity by agar spot-on lawn assay; as mentioned above, in 1.2. using postbiotics instate of cell suspension. An effective postbiotic was considered when the inhibition zone was presented.

4. Minimum inhibitory concentration (MIC) testing

Only the LCFS of *E. faecalis* PK1201 showing an inhibition zone in agar spot on lawn assay was further used to determine the quantitative antimicrobial activity of postbiotics on *C. difficile*. The MIC of the postbiotics was evaluated using the broth microdilution method: described by CLSI. The postbiotics were prepared in concentrations ranging from 500 to 0 mg/mL, in 96-well plate. Each well was inoculated with 100 µL (1×10^6 CFU/mL) of an overnight culture of *C. difficile* in an anaerobic condition at 37 °C for 48 hours. After 48 hours of incubation, each well was inspected for the presence and absence of turbidity, so as to determine the microorganism's growth. The MIC is the lowest concentration in which no turbidity was detected, implying that postbiotic inhibits *C. difficile* growth. Vancomycin was used as the positive control. Three independent experiments, with duplication samples, were performed.

5. Morphological changes of *C. difficile*

C. difficile's morphological changes were observed by scanning electron microscopy (SEM). Firstly, *C. difficile*

1×10^6 CFU/mL was cultured in a BHI broth with LCFS at the MICs, then the glass coverslips were added to the mixture and incubated at 37 °C for 24 hours under anaerobic conditions. After this, the glasses were prepared for SEM by washing with PBS then fixed in 2% glutaraldehyde for 2 hours. These glasses were then serially dehydrated in 25%, 50%, 75%, and 100% ethanol for 30 minutes for each concentration, respectively. Specimens were photographed at a magnification ranging from x1,000 to 10,000 under a Scanning Electron Microscope (JEOL CarryScope, JEOL Ltd., Tokyo, Japan) with an accelerating voltage of 20 kV²⁶.

6. Effect of postbiotics on anti-spore germination activity of *C. difficile*

6.1 Spore purification

C. difficile spores were generated by cultivating a single colony in 0.5% yeast extract and 0.1% L-cysteine, which were then incubated anaerobically at 37 °C overnight. The culture was then subculture into BHI agar with 0.1% L-cysteine, and incubation was continued at 37 °C for seven days. After the incubation period, spores were harvested and washed in PBS twice, followed by being suspended in PBS; containing 125 mM Tris, 200 mM EDTA, 0.3 mg/ml proteinase K, and 1% sarcosyl. The suspension was then incubated at 37 °C for two hours. After this, the spore suspension was centrifuged ten times in PBS at 6,500 g for 10 minutes each time. After the last wash, the spores were heated at 60 °C for 20 minutes to kill residual cells. Then, the amount of spores was calculated by plating an aliquot of spore dilution on BHI agar supplemented with 0.1% sodium taurocholate and incubating anaerobically for 48 hours before counting the colony on the plate²⁷.

6.2 Anti-spore germination test

The purified spores were used to evaluate the anti-spore germination activity of LCFS. The spore suspension, at a final concentration of 5×10^6 spores/mL, was added to the BHI broth supplement with 0.1% taurocholate together with postbiotics at 0.5 or 1xMICs.

These were then incubated anaerobically at 37 °C for 30 minutes. Following incubation, the taurocholate level was stopped by diluting the mixture. The germinated spores were counted by plate for the dilution on BHI agar and compared to total spores, which were determined by plating on BHI agar supplement with 0.1% taurocholate²⁸. Assays were performed in triplicate, and the percentage of germination was calculated as:

Percentage of germination = (CFU/mL on BHI plate)/ (CFU/mL on BHI agar supplement with 0.1% taurocholate plate) x 100)

7. Safety of LCFS on *Gelleria mellonella*

G. mellonella larvae at the final larval stage (body weight of 200–300 mg) were divided into two groups (10 larvae/group); 1) control (HEPES buffer); 2) LCFS group. The larvae were injected with 10 µL of LCFS to the last left proleg of each larva. Following injection, the larvae were stored in the plate at 37 °C, and the number of killed *G. mellonella* was recorded daily for seven days to analyze the survival rate²⁹. This experiment had been approved by the animal ethical committee: animal EC no. Ref.AI004/2022.

8. Statistical analysis

Statistical analyses were performed using GraphPad PRISM software. One-way ANOVA was performed for group difference comparison, and a p-value < 0.05 indicated a statistically significant difference. The Kaplan–Meier survival function of Stata software and log-rank test was applied to the *G. mellonella* survival rate analysis.

Results

1. Identification and characterization of bacteriocin-producing *E. faecalis* strains

The probiotic *E. faecalis* PK1201, characterized by a previous study, exhibited both phenotypic and genotypic characteristics as a bacteriocin-producing strain. The anti-*C. difficile* activity attributed to the bacteriocin-like substance was abolished by proteinase K treatment. The whole genomic analysis showed that after genome assembly, the total length of *E. faecalis* PK1201 was 2,678,694 bp. Moreover, the presence of a bacteriocin-encoding gene was explored. There was *enlA* coding for enterolysin A in *E. faecalis* PK1201 genome (Table 1).

2. Postbiotic preparation

From two postbiotic preparation methods, after screened activity by agar spot on lawn assay, the presence of an inhibition zone against *C. difficile* is shown in Table 2. From this result, we found that only LCFS presented with an inhibition zone; hence, LCFS was decided to be used in further steps.

3. Minimum inhibitory concentration (MIC) testing

Quantitative investigation of anti-*C. difficile* activity was carried out by evaluating MIC of postbiotics on *C. difficile* 630, using broth microdilution methods. Vancomycin was used as a positive control. The results are presented in Table 3: MIC of postbiotic was 18.2±6.9 mg/mL, while the MIC of vancomycin against *C. difficile* 630 was 0.7±0.3 µg/mL.

Table 1 Bacteriocins identified in bacterial strains by Bacteriocin Genome mining tool (BAGEL) 4

Strain	Bacteriocin	Scaffold number	Location	Identity (%)
PK1201	Enterolysin A	1	746,986–767,658	100.0

Table 2 Presentation of inhibition zones of postbiotics

Postbiotic	Inhibition zone
Bacterial cell lysate	–
LCFS	Present

LCFS=lyophilized cell free supernatant

Table 3 minimum inhibitory concentration (MIC) of postbiotic on toxigenic *C. difficile* 630

Postbiotic	MIC (mean±S.E.)
LCFS 1201	18.2±6.9 mg/mL
Vancomycin	0.7±0.3 µg/mL

MIC=minimum inhibitory concentration, LCFS=lyophilized cell free supernatant, S.E.=standard error, mg=milligram, µg=microgram, mL=milliliter

4. Morphology changes of *C. difficile*

The morphology changes of *C. difficile* cells were determined using SEM. The SEM results are illustrated in

Figure 1. LCFS at the MIC affects *C. difficile* after being treated for 24 hours by shortening the size of the cells compared to the control group, HEPES. Most cells were severely destroyed, and the formation of pores in the cell walls was observed.

5. Anti-spore germination activity

The activity of postbiotics on anti-spore germination is represented in Figure 2. The percentage of spore germination of *C. difficile* 630 was significantly reduced after being treated with LCFS of *E. faecalis* PK1201, at both 0.5x and 1x the MICs, compared to the untreated one indicating the great anti-spore germination activity of this postbiotic.

6. Safety of LCFS on *G. mellonella*

The safety of postbiotics prepared from potential probiotic *E. faecalis* PK1201 was tested using the *G. mellonella* model. All larvae injected with LCFS at the MIC survived within the 7-day period of incubation compared to that of negative control: this indicates the safety of certain LCFS (Figure 3).




Figure 1 Representative images of *C. difficile* 630 after treatment with lyophilized cell free supernatant (LCFS) of *E. faecalis* PK1201, or vancomycin under SEM. A; HEPES, B; LCFS PK1201, C; vancomycin. The bar represents 2 µm scale.




Figure 2 Effect of lyophilized cell free supernatant (LCFS) PK1201 postbiotic and vancomycin on the anti-spore germination activity of *C. difficile* 630. The results are the means of three independent experiments (mean±SEM) ***p-value< 0.001 vs the control group, HEPES




Figure 3 Toxicity of postbiotic lyophilized cell free supernatant (LCFS) PK1201 in *G. mellonella* model at the 1xMIC

Discussion

Antibiotic treatment for CDI is limited, due to the disruption of gut flora that might lead to a high rate of CDI recurrence³⁰. Postbiotics have recently gotten a lot of attention for treating bacterial infection diseases, because of their positive effects on the host without the risk of bacteremia, especially in immunocompromised individuals.¹¹ One exciting finding is the LCFS, postbiotic, established from potential probiotics *E. faecalis* strain PK 1201 that elucidated suppressive effects on *C. difficile* growth and caused cell damage. Another important finding is that postbiotics inhibit spore germination of *C. difficile* spores. Moreover, LCFS showed no acute toxicity in via *G. mellonella* model. These findings suggest a potential alternative strategy for preventing or treating CDI.

Postbiotics can be prepared from both nonviable bacteria components and bacterial metabolism substances that confer a health benefit on the host³¹. Thus, CFS which is prepared from probiotics during the growth of bacteria contains the secreted metabolites; including, antimicrobial substances, and should be considered as postbiotics, and able to be used as an alternative; thereby, replacing live bacteria³². Caly et al., 2017, found that *E. faecalis* strain 14, isolated from meconium, was able to inhibit *C. perfringens* by synthesis of enterocin DD14: the bacteriocin which was then purified from the culture supernatant³³. This work used LCFS produced from the neutralized CFS of bacteriocin-producing *E. faecalis* probiotic strains as postbiotics, and demonstrated the feasibility of using this postbiotic to prevent CDI.

To control CDI, one option is destroying *C. difficile* cells; therefore, postbiotic inhibitory activity was first investigated. The results showed that LCFS inhibited *C. difficile* 630 growth with MIC of 18.2 ± 6.9 mg/mL. Even though the MIC of the postbiotic was higher than that of the positive control, vancomycin, it is possible that the postbiotic contains many molecules that have not been purified. The possible mode of action in cell destruction

may possess by bacteriocin, the ribosomally synthesized antimicrobial substances. Previous studies demonstrated that *Enterococcus* spp. produce bacteriocin, including, enterocin A, enterocin AS-48, and enterocins L50A and L50B, that can form pores in the cell membrane of targeted bacteria. This makes them release important organelles that are followed by killing the desired bacterium³⁴.

In this present study, the activity in anti-*C. difficile* of bacteriocin-like inhibitory substances was destroyed after exposure to the proteolytic enzyme, indicating bacteriocin is the major active component. Furthermore, the genome of the *E. faecalis* strain was analyzed and it was found that the genes encode bacteriocin in the bacteria, including enterolysin A. As a result, these strains may produce bacteriocin. The enterolysin A showed antimicrobial activity against targeted bacteria, by pore formation in the membranes and the cell wall breakdown process, respectively³⁵. It is cell wall-degrading proteins that can degrade the targeted cell by hydrolyzing specific peptides of the bacterial cell wall³⁵. In this study, postbiotics might kill *C. difficile* cells through pore formation and cell wall disintegration. This was supported by the SEM results that show the morphology changes of *C. difficile* after being treated with postbiotics.

Another strategy that can directly minimize CDI is suppressing germination processes; when, *C. difficile* cells are exposed to specific environments, such as food restriction, quorum sensing and other stressful environments. This commences sporulation to create enough dormant spores to survive under those conditions. Spores are thought to cause recurrence, if they remain in the patient's stomach and germinate into the vegetative after the antibiotic treatment is finished or stopped. This is followed by producing the toxins that cause the primary symptoms of this disease³⁶. The spore germination process is induced by primary bile acids, such as cholic acid which is synthesized in human livers³⁷. On the other hand, the bile salt hydrolase (BSH) enzyme, which is found on the cell

surfaces, of many bacteria especially probiotics, catalyzes the deconjugation of primary bile acids to unconjugated bile salts resulting in reduced spore germination³⁸.

Interestingly, the results of this study found that *E. faecalis* PK1201 postbiotic dramatically inhibited the toxigenic *C. difficile* spore germination process; induced by taurocholic bile salt, compared to that of control. Thus, the anti-spore germination activity might be facilitated by the action of BSH enzymes. Romyasamit et al., 2020, also found that *E. faecalis* PK 1201 probiotics can produce BSH enzymes, which break down bile salt and are further implicated in the decline of *C. difficile* spore development¹⁰. In this study, the BSH enzymes might secrete out into the CFS used to prepare LCFS that shows anti-spore germination activity.

The effectiveness of postbiotics in *C. difficile* inhibition in vitro led to its possible application use as pharmaceutical product to prevent and treat CDI. However, the safety of postbiotic use is still required. In this study, acute toxicity was observed using the *G. mellonella* model. *G. mellonella* is a popular, primitive in vivo model for toxicity, antimicrobial activity and antivirulence tests³⁹. This model was used as an experimental model for the toxicity test of postbiotics against candidiasis⁴⁰. This present study demonstrated that LCFS PK1201 at the concentration of 1xMIC did not experience toxicity effects on *G. mellonella* comparable to that of the negative control: this indicates the safety of certain LCFS.

The overall results were able to conclude that LCFS from *E. faecalis* PK1201 that produced bacteriocin-like inhibitory substances inhibited *C. difficile* growth and the spore germination processes. LCFS showed no acute toxicity in *G. mellonella* at a concentration tested in this study. Although, the specific mechanism relating to the postbiotic effect in anti-spore germination is still not elucidated, LCFS might be employed as a possible, alternative approach to prevent and treat CDI.

Conclusion

LCFS from bacteriocin-like producing *E. faecalis* had antibacterial action against *C. difficile*, as well as the capacity to inhibit spore germination. In addition, LCFS at the MIC showed no acute toxicity at the tested concentration. It is possible that bacteriocin in LCFS is responsible for its antibacterial efficacy against *C. difficile*. As a result, LCFS might be used as a possible postbiotic against CDI.

Funding sources

The study was funded by the Development and Promotion of Science and Technology Talents Project (DPST), first placement 2588 [grant number 023/2558], through K.S. and P.L.

Conflict of interest

There are no potential conflicts of interest to declare.

References

- Centers for Disease Control and Prevention. *C. diff* (*Clostridioides difficile*) [homepage on the Internet]. Georgia: Centers for Disease Control and Prevention 2015 [cite 2022 Jul 1]. Available from: <https://www.cdc.gov/cdiff/Index.html>
- Kelly CP, LaMont JT. *Clostridium difficile* infection. Annu Rev Med 1998;49:375–90.
- Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in *Clostridium difficile* infection: a systematic review. PLoS One 2014;9:e98400.
- FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Cordoba: Report of Joint FAO/WHO Expert Consultation; 2001;p.1–4.
- O'sullivan L, Ross RP, Hill C. Potential of bacteriocin-producing lactic acid bacteria for improvements in food safety and quality. Biochimie 2002;84:593–604.
- Delves-Broughton J, Blackburn P, Evans RJ, Hugenholtz J. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek 1996;69:193–202.
- Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG,

- McDonald LC, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;31:431–55.
8. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of *Clostridium difficile*-associated diarrhoea. *Lancet Infect Dis* 2009;9:237–44.
 9. Mansour NM, Elkhatib WF, Aboshanab KM, Bahr M. Inhibition of *Clostridium difficile* in mice using a mixture of potential probiotic strains *Enterococcus faecalis* NM815, *E. faecalis* NM915, and *E. faecium* NM1015: novel candidates to control *C. difficile* infection (CDI). *Probiotics Antimicro Prot* 2018;10:511–22.
 10. Romyasmit C, Thatrimontrichai A, Aroonkesorn A, Chanket W, Ingviya N, Saengsuwan P, et al. *Enterococcus faecalis* Isolated From Infant Feces Inhibits Toxigenic *Clostridioides (Clostridium) difficile*. *Front Pediatr* 2020:612.
 11. Doron S, Snyderman DR. Risk and safety of probiotics. *Clin Infect Dis* 2015;60(Suppl_2):S129–34.
 12. Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EM, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. *Nat Rev Gastroenterol Hepatol* 2021;18:649–67.
 13. Šušaković J, Kos B, Beganović J, Leboš Pavunc A, Habjanič K, Matošić S. Antimicrobial activity—the most important property of probiotic and starter lactic acid bacteria. *Food Technol Biotechnol* 2010;48:296–307.
 14. De Almeida Júnior WL, da Silva Ferrari Í, de Souza JV, da Silva CD, da Costa MM, Dias FS. Characterization and evaluation of lactic acid bacteria isolated from goat milk. *Food Control* 2015;53:96–103.
 15. Aguilar-Toalá J, Garcia-Varela R, Garcia H, Mata-Haro V, González-Córdova A, Vallejo-Córdova B, et al. Postbiotics: an evolving term within the functional foods field. *Trends Food Sci Technol* 2018;75:105–14.
 16. Chu TW, Chen CN, Pan CY. Antimicrobial status of tilapia (*Oreochromis niloticus*) fed *Enterococcus adium* originally isolated from goldfish intestine. *Aquac Rep* 2020;17:100397.
 17. Breukink E, van Heusden HE, Vollmerhaus PJ, Swiezewska E, Brunner L, Walker S, et al. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. *J Biol Chem* 2003;278:19898–903.
 18. Redondo LM, Carrasco JMD, Redondo EA, Delgado F, Miyakawa MEF. *Clostridium perfringens* type E virulence traits involved in gut colonization. *PloS One* 2015;10:e0121305.
 19. Han S-K, Shin M-S, Park H-E, Kim S-Y, Lee W-K. Screening of bacteriocin-producing *Enterococcus faecalis* strains for antagonistic activities against *Clostridium perfringens*. *J Food Sci Anim Resour* 2014;34:614.
 20. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014;30:2114–20.
 21. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 2012;19:455–77.
 22. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. *Bioinformatics* 2013;29:1072–5.
 23. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014;30:2068–9.
 24. van Heel AJ, de Jong A, Song C, Viel JH, Kok J, Kuipers OP. BAGEL4: a user-friendly web server to thoroughly mine RiPPs and bacteriocins. *Nucleic Acids Res* 2018;46(W1):W278–81.
 25. Shin HS, Park SY, Lee DK, Kim S, An HM, Kim JR, et al. Hypocholesterolemic effect of sonication-killed *Bifidobacterium longum* isolated from healthy adult Koreans in high cholesterol fed rats. *Arch Pharmacol Res* 2010;33:1425–31.
 26. Lynch T, Chong P, Zhang J, Hizon R, Du T, Graham MR, et al. Characterization of a stable, metronidazole-resistant *Clostridium difficile* clinical isolate. *PloS One* 2013;8:e53757.
 27. Lawley TD, Croucher NJ, Yu L, Clare S, Sebahia M, Goulding D, et al. Proteomic and genomic characterization of highly infectious *Clostridium difficile* 630 spores. *J Bacteriol* 2009;191:5377–86.
 28. Carlson Jr PE, Kaiser AM, McColm SA, Bauer JM, Young VB, Aronoff DM, et al. Variation in germination of *Clostridium difficile* clinical isolates correlates to disease severity. *Anaerobe* 2015;33:64–70.
 29. Rossoni RD, De Barros PP, Mendonça IdC, Medina RP, Silva DHS, Fuchs BB, et al. The postbiotic activity of *Lactobacillus paracasei* 28.4 against *Candida auris*. *Front Cell Infect Microbiol* 2020:397. doi: 10.3389/fcimb.2020.00397
 30. Vincent C, Manges AR. Antimicrobial use, human gut microbiota and *Clostridium difficile* colonization and infection. *Antibiotics* 2015;4:230–53.

31. Morniroli D, Vizzari G, Consales A, Mosca F, Gianni ML. Postbiotic supplementation for children and newborn's health. *Nutrients* 2021;13:781.
32. Teame T, Wang A, Xie M, Zhang Z, Yang Y, Ding Q, et al. Paraprobiotics and postbiotics of probiotic Lactobacilli, their positive effects on the host and action mechanisms: A review. *Front Nutr* 2020:191.
33. Caly DL, Chevalier M, Flahaut C, Cudennec B, Al Atya AK, Chataigné G, et al. The safe enterocin DD14 is a leaderless two-peptide bacteriocin with anti-*Clostridium perfringens* activity. *Int J Antimicrob Agents* 2017;49:282–9.
34. Wu Y, Pang X, Wu Y, Liu X, Zhang X. Enterocins: classification, synthesis, antibacterial mechanisms and food applications. *Molecules* 2022;27:2258.
35. Nilsen T, Nes IF, Holo H. Enterolysin_A, a cell wall-degrading bacteriocin from *Enterococcus faecalis* LMG 2333. *Appl Environ Microbiol* 2003;69:2975–84.
36. Zhu D, Sorg JA, Sun X. *Clostridioides difficile* biology: sporulation, germination, and corresponding therapies for *C. difficile* infection. *Front Cell Infect Microbiol* 2018;8:29.
37. Thanissery R, Winston JA, Theriot CM. Inhibition of spore germination, growth, and toxin activity of clinically relevant *C. difficile* strains by gut microbiota derived secondary bile acids. *Anaerobe* 2017;45:86–100.
38. Bourgin M, Kriaa A, Mkaouer H, Mariaule V, Jablaoui A, Maguin E, et al. Bile Salt Hydrolases: At the crossroads of microbiota and human health. *Microorganisms* 2021;9:1122.
39. Thanissery R, Winston JA, Theriot CM. Inhibition of spore germination, growth, and toxin activity of clinically relevant *C. difficile* strains by gut microbiota derived secondary bile acids. *Anaerobe* 2017;45:86–100.
40. Thanissery R, Winston JA, Theriot CM. Inhibition of spore germination, growth, and toxin activity of clinically relevant *C. difficile* strains by gut microbiota derived secondary bile acids. *Anaerobe* 2017;45:86–100.